Literature DB >> 8332912

Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.

C H Warden1, C C Hedrick, J H Qiao, L W Castellani, A J Lusis.   

Abstract

Concentrations of plasma high density lipoprotein (HDL) are inversely correlated with atherosclerotic coronary artery disease. The two most abundant protein constituents of HDL are apolipoproteins A-I and A-II (apoA-I and apoA-II). ApoA-I is required for assembly of HDL and, when overexpressed in transgenic mice, confers resistance to early atherosclerosis. The present studies reveal that transgenic mice that overexpress mouse apoA-II had elevated HDL-cholesterol concentrations but, nevertheless, exhibited increased atherosclerotic lesion development as compared to normal mice. The HDL in the transgenic mice was larger and had an increased ratio of apoA-II to apoA-I. Thus, both the composition and amount of HDL appear to be important determinants of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8332912     DOI: 10.1126/science.8332912

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  77 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

4.  Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.

Authors:  M Shimada; S Ishibashi; T Inaba; H Yagyu; K Harada; J I Osuga; K Ohashi; Y Yazaki; N Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 5.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

6.  Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?

Authors:  Alan T Remaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

7.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.

Authors:  A Inazu; X C Jiang; T Haraki; K Yagi; N Kamon; J Koizumi; H Mabuchi; R Takeda; K Takata; Y Moriyama
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Carboxy-terminal deletion of the HDL receptor reduces receptor levels in liver and steroidogenic tissues, induces hypercholesterolemia, and causes fatal heart disease.

Authors:  Rinku Pal; Qingen Ke; German A Pihan; Ayce Yesilaltay; Marsha L Penman; Li Wang; Chandramohan Chitraju; Peter M Kang; Monty Krieger; Olivier Kocher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-30       Impact factor: 4.733

9.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

10.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.